Skip to main content
. Author manuscript; available in PMC: 2021 Jan 21.
Published in final edited form as: Circulation. 2019 Dec 5;141(3):217–233. doi: 10.1161/CIRCULATIONAHA.119.042178

Figure 2: PDE10A expression is upregulated in human failing hearts.

Figure 2:

(A) PDE10A2 mRNA levels assessed by qPCR in human non-failing or failing heart tissues, normalized to GAPDH; n=5 for non-failing hearts; n=12 for failing hearts. (B) PDE10A protein levels measured by western blotting in human non-failing or failing heart tissues; bar graph shows the average of n=5 for non-failing hearts and n=10 for failing hearts. (C) PDE10A cAMP-hydrolyzing activity in human non-failing or failing heart tissues; n=5 for non-failing hearts; n=9 for failing hearts. (D) Immuno-histochemistry staining of PDE10A in the human non-failing and failing heart tissues. Arrows indicate activated cardiac fibroblasts (CFs). Asterisks indicate cardiac myocytes (CMs). Scale bars: 100 μm. Similar results were obtained from 3 pairs of tissue samples. Statistics in A-C were performed using a student t-test. *P < 0.05